KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Total Current Liabilities: 2009-2025

Historic Total Current Liabilities for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Sep 2025 value amounting to $11.5 billion.

  • Teva Pharmaceutical Industries' Total Current Liabilities fell 16.71% to $11.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $11.5 billion, marking a year-over-year decrease of 16.71%. This contributed to the annual value of $12.8 billion for FY2024, which is 4.48% up from last year.
  • As of Q3 2025, Teva Pharmaceutical Industries' Total Current Liabilities stood at $11.5 billion, which was down 3.12% from $11.9 billion recorded in Q2 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Total Current Liabilities peaked at $13.8 billion during Q3 2024, and registered a low of $10.4 billion during Q1 2023.
  • Over the past 3 years, Teva Pharmaceutical Industries' median Total Current Liabilities value was $11.9 billion (recorded in 2025), while the average stood at $12.2 billion.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first soared by 32.48% in 2024, then fell by 19.11% in 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Total Current Liabilities (Quarterly) stood at $11.0 billion in 2021, then climbed by 4.01% to $11.5 billion in 2022, then increased by 6.78% to $12.2 billion in 2023, then increased by 4.48% to $12.8 billion in 2024, then fell by 16.71% to $11.5 billion in 2025.
  • Its Total Current Liabilities was $11.5 billion in Q3 2025, compared to $11.9 billion in Q2 2025 and $11.2 billion in Q1 2025.